JP2004538477A5 - - Google Patents

Download PDF

Info

Publication number
JP2004538477A5
JP2004538477A5 JP2003520382A JP2003520382A JP2004538477A5 JP 2004538477 A5 JP2004538477 A5 JP 2004538477A5 JP 2003520382 A JP2003520382 A JP 2003520382A JP 2003520382 A JP2003520382 A JP 2003520382A JP 2004538477 A5 JP2004538477 A5 JP 2004538477A5
Authority
JP
Japan
Prior art keywords
patient
level
antibody
time interval
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003520382A
Other languages
English (en)
Japanese (ja)
Other versions
JP4511830B2 (ja
JP2004538477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/026321 external-priority patent/WO2003015617A2/en
Publication of JP2004538477A publication Critical patent/JP2004538477A/ja
Publication of JP2004538477A5 publication Critical patent/JP2004538477A5/ja
Application granted granted Critical
Publication of JP4511830B2 publication Critical patent/JP4511830B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003520382A 2001-08-17 2002-08-16 アルツハイマー病のアッセイ方法 Expired - Lifetime JP4511830B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31322101P 2001-08-17 2001-08-17
US31322401P 2001-08-17 2001-08-17
US33498701P 2001-10-23 2001-10-23
PCT/US2002/026321 WO2003015617A2 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009208372A Division JP5162553B2 (ja) 2001-08-17 2009-09-09 アルツハイマー病のアッセイ方法

Publications (3)

Publication Number Publication Date
JP2004538477A JP2004538477A (ja) 2004-12-24
JP2004538477A5 true JP2004538477A5 (https=) 2006-01-05
JP4511830B2 JP4511830B2 (ja) 2010-07-28

Family

ID=27405654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003520382A Expired - Lifetime JP4511830B2 (ja) 2001-08-17 2002-08-16 アルツハイマー病のアッセイ方法
JP2009208372A Expired - Lifetime JP5162553B2 (ja) 2001-08-17 2009-09-09 アルツハイマー病のアッセイ方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009208372A Expired - Lifetime JP5162553B2 (ja) 2001-08-17 2009-09-09 アルツハイマー病のアッセイ方法

Country Status (10)

Country Link
EP (1) EP1416965B8 (https=)
JP (2) JP4511830B2 (https=)
AT (1) ATE381346T1 (https=)
CA (1) CA2457145C (https=)
CY (1) CY1107901T1 (https=)
DE (1) DE60224200T2 (https=)
DK (1) DK1416965T3 (https=)
ES (1) ES2295401T3 (https=)
PT (1) PT1416965E (https=)
WO (1) WO2003015617A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2121754E (pt) 2007-01-18 2015-05-11 Lilly Co Eli Fab de beta-amilóide peguilado
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2010093001A1 (ja) * 2009-02-13 2010-08-19 国立大学法人大阪大学 アルツハイマー病の診断方法および診断薬
WO2011070174A1 (en) 2009-12-11 2011-06-16 Araclon Biotech, S.L. Methods and reagents for improved detection of amyloid beta peptides
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
MX2016006584A (es) * 2013-11-20 2016-09-06 Univ Iowa Res Found Métodos y composiciones para tratar los depósitos de amiloide.
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
KR102496845B1 (ko) * 2018-08-08 2023-02-08 서울대학교산학협력단 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE667959T1 (de) * 1992-10-26 2000-04-20 Dale B Schenk VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID.
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos

Similar Documents

Publication Publication Date Title
JP2004538477A5 (https=)
Jusko et al. Plasma and tissue protein binding of drugs in pharmacokinetics
JP2002533680A5 (https=)
Pickup et al. Serum sialic acid concentration and coronary heart disease in NIDDM
JP2004532817A5 (https=)
KR101155294B1 (ko) 면역특이적으로 BLyS에 결합하는 항체
EA200500715A1 (ru) Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких
US20220402979A1 (en) Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
Ruocco et al. Life-threatening bullous dermatoses: Pemphigus vulgaris
JP2009173684A (ja) 腎臓結石疾患の予防のための希土類化合物の使用
JP2004517824A5 (https=)
AU2024201099A1 (en) Treatment and prevention of Alzheimer's Disease (AD)
JP2021534195A5 (https=)
CA2457145A1 (en) Assay method for alzheimer's disease
CN112312917A (zh) 用于治疗幻觉及其相关病症的方法和组合物
JP6725515B2 (ja) 小分子を用いた鉄欠乏生物における生理機能の回復
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
Zhu et al. Detection of IgE antibodies specific for 1-phenyl-2, 3-dimethyl-3-pyrazoline-5-one by RAST: a serological diagnostic method for sensitivity to pyrazoline drugs
DE60336063D1 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
EP3137094A1 (en) Treatment and prevention of alzheimer's disease (ad)
WO2002026193A3 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
Huang et al. Case report: atenolol overdose successfully treated with hemodialysis
JP2004507712A5 (https=)
JP5024695B2 (ja) 腎疾患治療剤
WO2001059452A3 (en) Method for diagnosing efficacy of xenotypic antibody therapy